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Polyglutamine expansion in the androgen receptor causes Kennedy’s disease. Two recent reports,
Cortes et al. (2014) in this issue of Neuron and Lieberman et al. (2014) in Cell Reports, raise the possibility
that targeting expression of the mutant protein in skeletal muscle, instead of the nervous system, may
mitigate manifestations of this disorder.Kennedy’s disease (spinal and bulbar
muscular atrophy [SBMA]) is a neuromus-
cular disorder characterized by slowly
progressive muscle weakness and atro-
phy, with degeneration of primary motor
neurons in the spinal cord and brainstem
of affected individuals (Sobue et al.,
1989). The disease is X-linked and caused
by expansion of a CAG repeat in the
first exon of the androgen receptor
(AR) gene, which leads to an expanded
polyglutamine tract in the AR protein
(La Spada et al., 1991).
Traditionally, SBMA has been viewed
as a cell-autonomous, primary motor
neuron disease. The neuronal death in
SBMA and other polyglutamine diseases
is at least in part due to a toxic gain-of-
function in the mutant protein. In addition
to the toxic effects of the AR, loss of
normal receptor function also contributes
to the disease phenotype, with some
patients having symptoms such as breast
enlargement and reduced fertility. There-
fore, an approach aimed at reducing
mutant protein levels without exacer-
bating the effects androgen deficiency
holds great promise as a potential treat-
ment for SBMA.
A number of different treatments have
been shown to protect against expanded
polyglutamine AR toxicity in SBMA animal
models; nevertheless, they have thus far
failed to result in effective treatment in
human clinical trials (Fischbeck, 2012).
This failure can be partly attributed to pit-
falls in preclinical research, such as lack
of blinding and starting treatment before
the onset of disease manifestations,
which is difficult to do in clinical trials.
The development of therapeutics would
also benefit from an improved under-standing of the mechanism of motor
neuron degeneration in SBMA. Non-
neuronal cells such as glial cells and
muscle probably play a critical role in
the pathogenesis of other motor neuron
diseases. Appreciation of this role not
only gives a better insight into the disease
mechanism but also opens new treatment
options, which is particularly desirable
for these disorders. For example, cells
outside the CNS may play a primary role
in spinal muscular atrophy (SMA). Periph-
eral targeting of antisense oligonucleo-
tides (ASOs) to restore expression of
survival motor neuron protein, deficiency
of which causes SMA, robustly amelio-
rates the disease manifestations in
SMAmice (Hua et al., 2011). Furthermore,
muscle-specific conditional rescue in
SMA mice leads to significant improve-
ment in weight, survival, and motor
behavior (Martinez et al., 2012).
Reports by Cortes et al. (2014) in this
issue of Neuron and Lieberman et al.
(2014) in Cell Reports challenge the tradi-
tional view of SBMA as a primary motor
neuron disease. These studies establish
muscle as a site of mutant AR toxicity
and suggest targeting mutant protein
expression in this tissue as an approach
for treating the disorder (Figure 1). Several
lines of evidence from previous studies
support a primary contribution of skeletal
muscle in the disease pathogenesis:
(1) muscle biopsies of SBMA patients
show features of both denervation and
myofiber degeneration (Soraru` et al.,
2008); (2) knockin mice expressing poly-
glutamine-expanded AR develop early
findings of myopathy with little or no
motor neuron loss (Yu et al., 2006); (3)
muscle-specific overexpression of wild-Neurontype, nonexpanded AR in mice is suffi-
cient to produce SBMA-like neuro-
muscular disease (Monks et al., 2007);
and (4) genetic overexpression of mus-
cle-specific IGF-1 or peripheral IGF-1
administration has been shown to miti-
gate SBMA symptoms in transgenic
mice (Palazzolo et al., 2009; Rinaldi
et al., 2012).
Cortes et al. (2014) explore the contri-
bution of muscle to SBMA pathogenesis
with a new conditional mouse model of
SBMA, BAC fxAR121Q, which expresses
a full-length human AR transgene with
121 CAG repeats under the control of
the endogenous AR promoter. The first
exon of the human AR transgene is
flanked by loxP sites, which allows
removal of the transcription start site by
Cre recombinase enzyme. In the absence
of Cre, fxAR121Q mice show mutant
AR transgene expression comparable
to endogenous mouse AR in mRNA, pro-
tein, and tissue distribution. Male mice
develop progressive muscle weakness,
weight loss, and reduced survival, similar
to other transgenic SBMAmousemodels.
Introduction of Cre recombinase under
the control of a ubiquitous promoter
(CMV-Cre) in fxAR121Q mice completely
abrogated mutant AR transgene expres-
sion in all tissues. Double transgenic
fxAR121Q/CMV-Cre mice were indistin-
guishable from nontransgenic littermates
and never developed SBMA manifesta-
tions, demonstrating complete mitigation
of mutant AR toxicity through Cre-medi-
ated recombination events in this model.
Next, Cortes et al. (2014) introduced
tissue-specific Cre expression driven by
a human skeletal actin (HSA-Cre) pro-
moter. fxAR121Q/HSA-Cre mice showed82, April 16, 2014 ª2014 Elsevier Inc. 251
Figure 1. Reducing Mutant AR Expression in Muscle Has Beneficial
Effects in SBMA Mouse Models
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AR transgene in skeletal
muscle. Although AR was still
expressed in the spinal cord,
and reduced motor neuron
soma size and accumulation
of mutant AR in nuclear inclu-
sions were unchanged in
these mice, muscle-specific
abrogation of AR increased
survival, suppressed weight
loss and weakness, and
increased the diameter of
motor axons. This study
demonstrates a primary role
of skeletal muscle in SBMA
pathogenesis in these mice
and justifies AR gene
silencing in muscle tissues
as a potential disease-modi-
fying strategy in patients.
By targeted reduction of
mutant AR using ASO tech-
nology, Lieberman et al.
(2014) took this approach
one step closer to the clinic.
The authors developed and
characterized ASOs selective
for human or mouse AR,
which suppressed AR mRNA
in a dose-dependent fashion
in cultured cells. Next, ASOs
were tested for their effects
on SBMA manifestations intwo mouse models: AR113Q knockin
mice that have a CAG repeat expansion
in the endogenous mouse AR locus
and the fxAR121Q mice described by
Cortes et al. (2014). ASOs were delivered
subcutaneously, before or at the time of
disease onset, and found to markedly
suppress AR expression in skeletal mus-
cle but not spinal cord in both mouse
models. ASO treatment rescued weight
loss, muscle weakness, abnormal gene
expression, and lethality in the mice,
without altering testosterone levels.
Notably, AR suppression by ASOs was
maintained up to 10weeks after cessation
of treatment. Lowering AR expression in
the spinal cord, achieved through intra-
ventricular delivery of ASO, surprisingly
did not modify disease manifestations
in the fxAR121Q mice, indicating that the
main problem in these mice is not in the
CNS and that the best way to correct it
is with peripheral rather than central
treatment.252 Neuron 82, April 16, 2014 ª2014 ElsevierWhile it remains to be seen whether AR
suppression reverses SBMA pathology
at more advanced disease stages, the
findings byCortes et al. (2014) and Lieber-
man et al. (2014) have important impli-
cations. The data presented confirm
previous reports, which place muscle
next to motor neurons as an important
contributor to SBMA pathogenesis
(Monks et al., 2007; Soraru` et al., 2008).
Moreover, the two studies show that
mutant AR accumulation in motor neu-
rons may not be sufficient for polyglut-
amine toxicity in SBMA models, and
they indicate that targeting mutant AR
in muscle can ameliorate the functional
defects associated with SBMA.
Targeting the periphery for treatment
has practical advantages over delivery
to the CNS. This approach would limit
the side effects related to AR reduction
in the CNS, such as decreased libido,
which are known adverse effects of
androgen reduction therapy. Also, skel-Inc.etal muscle is readily acces-
sible; unlike the spinal cord, it
can be biopsied for pharma-
codynamic measures of drug
effect.
Based on the two reports
presented here, it is tempting
to think of SBMA as a muscle
disease rather than a motor
neuron disease. However, a
confounding factor in the
fxAR121Q model may be re-
tained expression of endoge-
nous mouse AR, which has
previously been shown to
modulate mutant AR toxicity
in vivo (Thomas et al., 2006).
It should be noted that in hu-
mans the AR gene is located
on the X chromosome, and
affected individuals, who are
male, have only the one mu-
tated copy. While this genetic
context is better recapitulated
in the AR113Q knockin model,
these mice have a relatively
mild muscle phenotype and,
similarly to fxAR121Q mice,
motor neuron loss has not
been reported. In the knockin
mice, the primary cause of
death is urinary retention
(Yu et al., 2006), which is not
a problem in SBMA patients.There is clear evidence that loss of
normal receptor function also contributes
to the disease phenotype. A possibility
remains that a decrease in AR protein
may further exacerbate symptoms of
androgen insensitivity and compromise
remaining muscle strength as well as
perceived well-being in a clinical setting.
Functional reduction of AR via ligand
removal has been tried in SBMA patients
with mixed results. Pharmacological
manipulation of the AR ligand testos-
terone, either through chemical castration
or alpha-reductase inhibition, did not
significantly improve primary clinical out-
comes in randomized, placebo-controlled
studies (Katsuno et al., 2010; Ferna´ndez-
Rhodes et al., 2011).
Further work using in vitro culture and
animal models is needed to answer re-
maining questions. What aspects of
muscle dysfunction promote the disease
process?Howdoes themuscle pathology
in SBMA contribute to motor neuron
Neuron
Previewsdegeneration in SBMA? Will amelioration
of the disease by targeting muscle
uncover other CNS manifestations?
Answering these questions will help in
translating this potential treatment option
into effective treatment in patients.
In summary, the reports by Cortes
et al. (2014) and Lieberman et al. (2014)
emphasize the role of skeletal muscle
as an important contributor to SBMA
pathogenesis and underscore the impor-
tance of exploring approaches targeting
peripheral tissues for treatment.
Clearly, in this disease the muscle
matters.
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Microglia are highly dynamic components of the innate immune system. In this issue of Neuron, Elmore et al.
(2014) report that global depletion of microglia triggers mobilization of latent microglial progenitors
throughout the CNS, resulting in rapid repopulation.There is a common misconception that
the adult CNS has a limited capacity for
repair and regeneration. While this is true
for most neuronal populations, many
types of glial cells exhibit remarkable
homeostasis and strive to maintain a
constant density in response to internal
or external perturbations. Understanding
how this process of cellular maintenance
is regulated, and identifying the progeni-
tors responsible for replenishing distinct
classes of glia, could lead to new strate-
gies for speeding recovery from injuryand limiting the abnormal cellular prolif-
eration that leads to brain cancer. In this
issue of Neuron, Elmore et al. (2014)
describe a new method to deplete micro-
glia from the adult CNS and use this
approach to investigate how homeostasis
of microglia is achieved and the broader
roles of these ubiquitous glial cells in con-
trolling behavior.
Unlike other glial cells (astroglia, oligo-
dendroglia), microglia are formed outside
the developing CNS from hematopoietic
progenitors in the yolk sac and migrateinto the CNS before the blood-brain bar-
rier (BBB) is formed (Kierdorf et al.,
2013). There they expand through prolif-
eration to establish a grid-like distribution
throughout the CNS. Microglia are crucial
for the innate immune response and
secrete numerous cytokines and chemo-
kines to regulate tissue repair and can
transform into highly migratory cells that
engulf dead cells and debris, playing a
crucial role in CNSdevelopment, recovery
from injury, and progression of disease.
Recent studies suggest that these glial82, April 16, 2014 ª2014 Elsevier Inc. 253
